000141883 001__ 141883
000141883 005__ 20240229105134.0
000141883 0247_ $$2doi$$a10.1186/s12964-018-0301-7
000141883 0247_ $$2pmid$$apmid:30466445
000141883 0247_ $$2pmc$$apmc:PMC6251197
000141883 0247_ $$2altmetric$$aaltmetric:51566939
000141883 037__ $$aDKFZ-2018-02140
000141883 041__ $$aeng
000141883 082__ $$a570
000141883 1001_ $$aTomek, Petr$$b0
000141883 245__ $$aImprinted and ancient gene: a potential mediator of cancer cell survival during tryptophan deprivation.
000141883 260__ $$aLondon$$bBiomed Central$$c2018
000141883 3367_ $$2DRIVER$$aarticle
000141883 3367_ $$2DataCite$$aOutput Types/Journal article
000141883 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1544433112_542
000141883 3367_ $$2BibTeX$$aARTICLE
000141883 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141883 3367_ $$00$$2EndNote$$aJournal Article
000141883 520__ $$aDepletion of tryptophan and the accumulation of tryptophan metabolites mediated by the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1), trigger immune cells to undergo apoptosis. However, cancer cells in the same microenvironment appear not to be affected. Mechanisms whereby cancer cells resist accelerated tryptophan degradation are not completely understood. We hypothesize that cancer cells co-opt IMPACT (the product of IMPrinted and AnCienT gene), to withstand periods of tryptophan deficiency.A range of bioinformatic techniques including correlation and gene set variation analyses was applied to genomic datasets of cancer (The Cancer Genome Atlas) and normal (Genotype Tissue Expression Project) tissues to investigate IMPACT's role in cancer. Survival of IMPACT-overexpressing GL261 glioma cells and their wild type counterparts cultured in low tryptophan media was assessed using fluorescence microscopy and MTT bio-reduction assay. Expression of the Integrated Stress Response proteins was measured using Western blotting.We found IMPACT to be upregulated and frequently amplified in a broad range of clinical cancers relative to their non-malignant tissue counterparts. In a subset of clinical cancers, high IMPACT expression associated with decreased activity of pathways and genes involved in stress response and with increased activity of translational regulation such as the mTOR pathway. Experimental studies using the GL261 glioma line showed that cells engineered to overexpress IMPACT, gained a survival advantage over wild-type lines when cultured under limiting tryptophan concentrations. No significant difference in the expression of proteins in the Integrated Stress Response pathway was detected in tryptophan-deprived GL261 IMPACT-overexpressors compared to that in wild-type cells. IMPACT-overexpressing GL261 cells but not their wild-type counterparts, showed marked enlargement of their nuclei and cytoplasmic area when stressed by tryptophan deprivation.The bioinformatics data together with our laboratory studies, support the hypothesis that IMPACT mediates a protective mechanism allowing cancer cells to overcome microenvironmental stresses such as tryptophan deficiency.
000141883 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141883 588__ $$aDataset connected to CrossRef, PubMed,
000141883 7001_ $$aGore, Shanti K$$b1
000141883 7001_ $$aPotts, Chloe L$$b2
000141883 7001_ $$aPrint, Cristin G$$b3
000141883 7001_ $$aBlack, Michael A$$b4
000141883 7001_ $$aHallermayr, Ariane$$b5
000141883 7001_ $$0P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc$$aKilian, Michael$$b6$$udkfz
000141883 7001_ $$aSattlegger, Evelyn$$b7
000141883 7001_ $$00000-0002-9745-2868$$aChing, Lai-Ming$$b8
000141883 773__ $$0PERI:(DE-600)2126315-2$$a10.1186/s12964-018-0301-7$$gVol. 16, no. 1, p. 88$$n1$$p88$$tCell communication and signaling$$v16$$x1478-811X$$y2018
000141883 909CO $$ooai:inrepo02.dkfz.de:141883$$pVDB
000141883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000141883 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141883 9141_ $$y2018
000141883 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL COMMUN SIGNAL : 2017
000141883 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141883 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141883 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141883 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141883 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000141883 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000141883 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000141883 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000141883 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141883 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141883 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141883 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141883 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141883 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141883 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELL COMMUN SIGNAL : 2017
000141883 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x0
000141883 980__ $$ajournal
000141883 980__ $$aVDB
000141883 980__ $$aI:(DE-He78)G160-20160331
000141883 980__ $$aUNRESTRICTED